SK3632003A3 - Benzodiazepine derivatives, pharmaceutical composition comprising same and their use - Google Patents
Benzodiazepine derivatives, pharmaceutical composition comprising same and their use Download PDFInfo
- Publication number
- SK3632003A3 SK3632003A3 SK363-2003A SK3632003A SK3632003A3 SK 3632003 A3 SK3632003 A3 SK 3632003A3 SK 3632003 A SK3632003 A SK 3632003A SK 3632003 A3 SK3632003 A3 SK 3632003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- carbon atoms
- mmol
- substituted
- broad
- Prior art date
Links
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title claims abstract description 34
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title claims abstract 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 108010074860 Factor Xa Proteins 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- -1 methylenedioxy group Chemical group 0.000 claims description 474
- 125000004432 carbon atom Chemical group C* 0.000 claims description 250
- 125000001424 substituent group Chemical group 0.000 claims description 176
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 125000001072 heteroaryl group Chemical group 0.000 claims description 75
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 72
- 125000003118 aryl group Chemical group 0.000 claims description 62
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 60
- 229910052736 halogen Inorganic materials 0.000 claims description 58
- 150000002367 halogens Chemical class 0.000 claims description 58
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 39
- 125000004076 pyridyl group Chemical group 0.000 claims description 38
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 33
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 32
- 125000005936 piperidyl group Chemical group 0.000 claims description 32
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 25
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 23
- 229910052801 chlorine Inorganic materials 0.000 claims description 22
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 239000000460 chlorine Substances 0.000 claims description 19
- 125000004429 atom Chemical group 0.000 claims description 17
- 125000006828 (C2-C7) alkoxycarbonyl group Chemical group 0.000 claims description 16
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 16
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 16
- 229910052794 bromium Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 16
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000004193 piperazinyl group Chemical group 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 13
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 13
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 13
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 12
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 12
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 12
- 208000007536 Thrombosis Diseases 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 10
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 229930192474 thiophene Chemical group 0.000 claims description 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000005080 alkoxycarbonylalkenyl group Chemical group 0.000 claims description 6
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 208000005189 Embolism Diseases 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000006573 (C1-C10) heteroaryl group Chemical group 0.000 claims description 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 4
- 230000023555 blood coagulation Effects 0.000 claims description 4
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Chemical group 0.000 claims description 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims description 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
- 125000006697 (C1-C3) aminoalkyl group Chemical group 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 206
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 510
- 239000000243 solution Substances 0.000 description 414
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 393
- 239000002904 solvent Substances 0.000 description 321
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 316
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 310
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 231
- 230000015572 biosynthetic process Effects 0.000 description 223
- 238000003786 synthesis reaction Methods 0.000 description 221
- 239000012043 crude product Substances 0.000 description 183
- 238000005481 NMR spectroscopy Methods 0.000 description 169
- 238000005160 1H NMR spectroscopy Methods 0.000 description 156
- 238000006243 chemical reaction Methods 0.000 description 136
- 239000011541 reaction mixture Substances 0.000 description 135
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 126
- 238000000605 extraction Methods 0.000 description 126
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 125
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 115
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 99
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 92
- 239000000203 mixture Substances 0.000 description 92
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 89
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 75
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- 238000001704 evaporation Methods 0.000 description 51
- 230000008020 evaporation Effects 0.000 description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 48
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 45
- 239000000047 product Substances 0.000 description 44
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 36
- 235000011054 acetic acid Nutrition 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 239000000741 silica gel Substances 0.000 description 30
- 229910002027 silica gel Inorganic materials 0.000 description 30
- 238000004440 column chromatography Methods 0.000 description 29
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 22
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 21
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 21
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 20
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 20
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000012312 sodium hydride Substances 0.000 description 15
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 14
- 150000001557 benzodiazepines Chemical class 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- UCQALSHTLAUIFM-UHFFFAOYSA-N 1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-4,5-dihydro-3h-1,4-benzodiazepin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.O=C1CNCC2=CC=CC=C2N1CC(CC1)CCN1C1=CC=NC=C1 UCQALSHTLAUIFM-UHFFFAOYSA-N 0.000 description 13
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- WUNBZIHKUUZXET-UHFFFAOYSA-N 1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-4,5-dihydro-3h-1,4-benzodiazepin-2-one Chemical compound O=C1CNCC2=CC=CC=C2N1CC(CC1)CCN1C1=CC=NC=C1 WUNBZIHKUUZXET-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- VTXGCQMVXZSHIR-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-3,5-dihydro-1h-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)NC2=CC=CC=C2C1 VTXGCQMVXZSHIR-UHFFFAOYSA-N 0.000 description 11
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 235000019260 propionic acid Nutrition 0.000 description 11
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- AZIZBYRGIGKTLW-UHFFFAOYSA-N 1,4-diazepin-2-one Chemical compound O=C1C=NC=CC=N1 AZIZBYRGIGKTLW-UHFFFAOYSA-N 0.000 description 10
- LXXRSFUXYOQAKA-UHFFFAOYSA-N 4-(2,5-dihydropyrrole-1-carbonyl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1C(=O)N1CC=CC1 LXXRSFUXYOQAKA-UHFFFAOYSA-N 0.000 description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- VOXANKRFRUBRGI-UHFFFAOYSA-N ethylamino acetate hydrochloride Chemical compound Cl.CCNOC(C)=O VOXANKRFRUBRGI-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 239000011593 sulfur Substances 0.000 description 8
- WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 7
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 5
- TVDJEUFIGWDQHS-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(chloromethyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(CCl)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 TVDJEUFIGWDQHS-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 5
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 4
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 206010038563 Reocclusion Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 208000032109 Transient ischaemic attack Diseases 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 201000010875 transient cerebral ischemia Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XQFULEXIJCGUFL-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(pyrrolidine-1-carbonyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CCCC2)C2=CC=CC=C2C1 XQFULEXIJCGUFL-UHFFFAOYSA-N 0.000 description 3
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 3
- QKRHVBYPKIQCQG-UHFFFAOYSA-N 4-[[4-(4-chlorobenzoyl)-2-oxo-3,5-dihydro-1,4-benzodiazepin-1-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 QKRHVBYPKIQCQG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229940122388 Thrombin inhibitor Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- DGEMSNCJSXCRRM-UHFFFAOYSA-N ethyl 2-[(4-bromo-2-nitrophenyl)methyl-(4-chlorobenzoyl)amino]acetate Chemical compound C=1C=C(Cl)C=CC=1C(=O)N(CC(=O)OCC)CC1=CC=C(Br)C=C1[N+]([O-])=O DGEMSNCJSXCRRM-UHFFFAOYSA-N 0.000 description 3
- BEXGIUAYHSHIDA-UHFFFAOYSA-N ethyl 2-amino-3-(2-nitrophenyl)propanoate Chemical compound CCOC(=O)C(N)CC1=CC=CC=C1[N+]([O-])=O BEXGIUAYHSHIDA-UHFFFAOYSA-N 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 125000004888 n-propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- JWEGFNFVTHGYLT-UHFFFAOYSA-N tert-butyl 2-oxo-3,5-dihydro-1h-1,4-benzodiazepine-4-carboxylate Chemical compound N1C(=O)CN(C(=O)OC(C)(C)C)CC2=CC=CC=C21 JWEGFNFVTHGYLT-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000003868 thrombin inhibitor Substances 0.000 description 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 2
- ROXAFEIDZVHGFX-UHFFFAOYSA-N 1,3,4,5-tetrahydro-1,4-benzodiazepin-2-one Chemical compound N1C(=O)CNCC2=CC=CC=C21 ROXAFEIDZVHGFX-UHFFFAOYSA-N 0.000 description 2
- BQTRMYJYYNQQGK-UHFFFAOYSA-N 1-(bromomethyl)-4-iodobenzene Chemical compound BrCC1=CC=C(I)C=C1 BQTRMYJYYNQQGK-UHFFFAOYSA-N 0.000 description 2
- SSNGIEIAZVPAKM-UHFFFAOYSA-N 1-[(4-aminophenyl)methyl]-4-(4-chlorobenzoyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(N)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 SSNGIEIAZVPAKM-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- ATCRIUVQKHMXSH-UHFFFAOYSA-N 2,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1Cl ATCRIUVQKHMXSH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WNUVBYQFZRFRIY-UHFFFAOYSA-N 2-[4-(4-chlorobenzoyl)-2-oxo-3,5-dihydro-1,4-benzodiazepin-1-yl]-n-pyridin-3-ylacetamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC(=O)NC=2C=NC=CC=2)C2=CC=CC=C2C1 WNUVBYQFZRFRIY-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- MQNHKLMHRZYTBZ-UHFFFAOYSA-N 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C(O)=O)=C1 MQNHKLMHRZYTBZ-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- XSZKKLMRTOVSGL-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-2-oxo-3,5-dihydro-1,4-benzodiazepine-7-carboxylic acid Chemical compound O=C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC(C(=O)O)=CC=C2N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 XSZKKLMRTOVSGL-UHFFFAOYSA-N 0.000 description 2
- YRSJVHLHBXBOID-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-6-(trifluoromethyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound O=C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC=2C(C(F)(F)F)=CC=CC=2N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 YRSJVHLHBXBOID-UHFFFAOYSA-N 0.000 description 2
- HMZWYBDUMQQLLZ-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-7-(dimethylamino)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound O=C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC(N(C)C)=CC=C2N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 HMZWYBDUMQQLLZ-UHFFFAOYSA-N 0.000 description 2
- VJQUCOQVMUTENY-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-(3-hydroxypropyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(CCCO)=CC=C2CN(C(=O)C=2C=CC(Cl)=CC=2)CC(=O)N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 VJQUCOQVMUTENY-UHFFFAOYSA-N 0.000 description 2
- JRHVSHFOPDVGTL-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(pyrrolidin-1-ylmethyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(CN3CCCC3)=CC=2)C2=CC=CC=C2C1 JRHVSHFOPDVGTL-UHFFFAOYSA-N 0.000 description 2
- ZCHDIOOOKFBLGA-UHFFFAOYSA-N 4-(4-methoxybenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(OC)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 ZCHDIOOOKFBLGA-UHFFFAOYSA-N 0.000 description 2
- BHFVBSKTJDQGRP-UHFFFAOYSA-N 4-(5-chloropyridine-2-carbonyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound N1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CC=CC2)C2=CC=CC=C2C1 BHFVBSKTJDQGRP-UHFFFAOYSA-N 0.000 description 2
- XTXKPVXZEDERLE-UHFFFAOYSA-N 4-(pyrrolidine-1-carbonyl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1C(=O)N1CCCC1 XTXKPVXZEDERLE-UHFFFAOYSA-N 0.000 description 2
- LNKHBRDWRIIROP-UHFFFAOYSA-N 4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C=C1 LNKHBRDWRIIROP-UHFFFAOYSA-N 0.000 description 2
- NPSMMQVDTBJFKY-UHFFFAOYSA-N 4-[[4-(4-chlorobenzoyl)-2-oxo-3,5-dihydro-1,4-benzodiazepin-1-yl]methyl]-n,n-dimethylbenzenecarboximidamide Chemical compound C1=CC(C(=N)N(C)C)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 NPSMMQVDTBJFKY-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- ZLBDQAQNEFGFAV-UHFFFAOYSA-N 5-chloropyridine-2-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=C(Cl)C=N1 ZLBDQAQNEFGFAV-UHFFFAOYSA-N 0.000 description 2
- VJEHZNNQOFQLEU-UHFFFAOYSA-N 8-chloro-4-(4-chlorobenzoyl)-1-[(1-piperidin-4-yloxycyclohexa-2,4-dien-1-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC2(C=CC=CC2)OC2CCNCC2)C2=CC(Cl)=CC=C2C1 VJEHZNNQOFQLEU-UHFFFAOYSA-N 0.000 description 2
- JDXJESMTFQJWNM-UHFFFAOYSA-N 8-chloro-4-(4-chlorobenzoyl)-3,5-dihydro-1h-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)NC2=CC(Cl)=CC=C2C1 JDXJESMTFQJWNM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- SJYWVKMSFDPIPT-UHFFFAOYSA-N C1=CC(=CC=C1C(=O)CCOC(=O)CNCC2=C(C=C(C=C2)C(=O)O)N)Cl Chemical compound C1=CC(=CC=C1C(=O)CCOC(=O)CNCC2=C(C=C(C=C2)C(=O)O)N)Cl SJYWVKMSFDPIPT-UHFFFAOYSA-N 0.000 description 2
- RTJKAOAKEKYTOV-UHFFFAOYSA-N CCOC(=O)C(CC1=C(C=CC(=C1)C)[N+](=O)[O-])N Chemical compound CCOC(=O)C(CC1=C(C=CC(=C1)C)[N+](=O)[O-])N RTJKAOAKEKYTOV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 208000006193 Pulmonary infarction Diseases 0.000 description 2
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- MJUJXFBTEFXVKU-UHFFFAOYSA-N diethyl phosphonate Chemical compound CCOP(=O)OCC MJUJXFBTEFXVKU-UHFFFAOYSA-N 0.000 description 2
- ILQWEGWJNFRRNB-UHFFFAOYSA-N ethyl 2-[(2-amino-6-chlorophenyl)methyl-(4-chlorobenzoyl)amino]acetate Chemical compound C=1C=C(Cl)C=CC=1C(=O)N(CC(=O)OCC)CC1=C(N)C=CC=C1Cl ILQWEGWJNFRRNB-UHFFFAOYSA-N 0.000 description 2
- VHNWVGJDQFOOBL-UHFFFAOYSA-N ethyl 2-[(2-amino-6-methoxyphenyl)methyl-(4-chlorobenzoyl)amino]acetate Chemical compound C=1C=C(Cl)C=CC=1C(=O)N(CC(=O)OCC)CC1=C(N)C=CC=C1OC VHNWVGJDQFOOBL-UHFFFAOYSA-N 0.000 description 2
- UDOKHDIABJRKJE-UHFFFAOYSA-N ethyl 2-[(4-chlorobenzoyl)-[(5-fluoro-2-nitrophenyl)methyl]amino]acetate Chemical compound C=1C=C(Cl)C=CC=1C(=O)N(CC(=O)OCC)CC1=CC(F)=CC=C1[N+]([O-])=O UDOKHDIABJRKJE-UHFFFAOYSA-N 0.000 description 2
- JMIWXOYEFIAKBO-UHFFFAOYSA-N ethyl 2-amino-3-(2-chloro-6-nitrophenyl)propanoate Chemical compound CCOC(=O)C(N)CC1=C(Cl)C=CC=C1[N+]([O-])=O JMIWXOYEFIAKBO-UHFFFAOYSA-N 0.000 description 2
- POQSUGPFFCSANW-UHFFFAOYSA-N ethyl 2-amino-3-(4-bromo-2-nitrophenyl)propanoate Chemical compound CCOC(=O)C(N)CC1=CC=C(Br)C=C1[N+]([O-])=O POQSUGPFFCSANW-UHFFFAOYSA-N 0.000 description 2
- AFZRDVMZCAMXOS-UHFFFAOYSA-N ethyl 2-amino-3-(4-chloro-2-nitrophenyl)propanoate Chemical compound CCOC(=O)C(N)CC1=CC=C(Cl)C=C1[N+]([O-])=O AFZRDVMZCAMXOS-UHFFFAOYSA-N 0.000 description 2
- FKFZKXJVTUYINO-UHFFFAOYSA-N ethyl 2-amino-3-(5-fluoro-2-nitrophenyl)propanoate Chemical compound CCOC(=O)C(N)CC1=CC(F)=CC=C1[N+]([O-])=O FKFZKXJVTUYINO-UHFFFAOYSA-N 0.000 description 2
- VEKPLQUWLHWELY-UHFFFAOYSA-N ethyl 2-amino-3-[2-nitro-4-(trifluoromethyl)phenyl]propanoate Chemical compound CCOC(=O)C(N)CC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O VEKPLQUWLHWELY-UHFFFAOYSA-N 0.000 description 2
- VICDKVHFGJXMJE-UHFFFAOYSA-N ethyl 2-amino-3-[2-nitro-6-(trifluoromethyl)phenyl]propanoate Chemical compound CCOC(=O)C(N)CC1=C([N+]([O-])=O)C=CC=C1C(F)(F)F VICDKVHFGJXMJE-UHFFFAOYSA-N 0.000 description 2
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 2
- BEBBWTPLBRZIOF-UHFFFAOYSA-N ethyl 5-chloropyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)C=N1 BEBBWTPLBRZIOF-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- JUOXYWXXPHUSAI-UHFFFAOYSA-N ethylamino acetate Chemical compound CCNOC(C)=O JUOXYWXXPHUSAI-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- HZHSUNCZJRTJFZ-UHFFFAOYSA-N methyl 3-[[(2-ethoxy-2-oxoethyl)amino]methyl]-4-nitrobenzoate Chemical compound CCOC(=O)CNCC1=CC(C(=O)OC)=CC=C1[N+]([O-])=O HZHSUNCZJRTJFZ-UHFFFAOYSA-N 0.000 description 2
- RMVFKUFCEPBVNT-UHFFFAOYSA-N methyl 4-amino-3-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]benzoate Chemical compound COC(=O)C1=CC=C(N)C(CNCC(=O)OCCC(=O)C=2C=CC(Cl)=CC=2)=C1 RMVFKUFCEPBVNT-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000007575 pulmonary infarction Effects 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BSZYGTODZAFRDC-UHFFFAOYSA-N tert-butyl 4-(4-formylphenoxy)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(C=O)C=C1 BSZYGTODZAFRDC-UHFFFAOYSA-N 0.000 description 2
- CNGPGEWCEFUHAA-UHFFFAOYSA-N tert-butyl 8-chloro-2-oxo-3,5-dihydro-1h-1,4-benzodiazepine-4-carboxylate Chemical compound N1C(=O)CN(C(=O)OC(C)(C)C)CC2=CC=C(Cl)C=C21 CNGPGEWCEFUHAA-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- BNGWWBRWRZGBLP-UHFFFAOYSA-N (1-pyridin-4-ylpiperidin-4-yl)methanol Chemical compound C1CC(CO)CCN1C1=CC=NC=C1 BNGWWBRWRZGBLP-UHFFFAOYSA-N 0.000 description 1
- QXBWTYBCNFKURT-UHFFFAOYSA-N (2-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=CC=C1B(O)O QXBWTYBCNFKURT-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- MTGRTTYTCFLDCE-UHFFFAOYSA-N (4-chlorophenyl)-(1,2,3,5-tetrahydro-1,4-benzodiazepin-4-yl)methanone Chemical compound Clc1ccc(cc1)C(=O)N1CCNc2ccccc2C1 MTGRTTYTCFLDCE-UHFFFAOYSA-N 0.000 description 1
- ULYZTHQGJXPEFT-UHFFFAOYSA-N (5-chloro-2-nitrophenyl)methanol Chemical compound OCC1=CC(Cl)=CC=C1[N+]([O-])=O ULYZTHQGJXPEFT-UHFFFAOYSA-N 0.000 description 1
- CWOZQRGVHQIIJL-UHFFFAOYSA-N (5-fluoro-2-nitrophenyl)methanol Chemical compound OCC1=CC(F)=CC=C1[N+]([O-])=O CWOZQRGVHQIIJL-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- YZIFVWOCPGPNHB-UHFFFAOYSA-N 1,2-dichloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C(Cl)=C1 YZIFVWOCPGPNHB-UHFFFAOYSA-N 0.000 description 1
- RGGLEJFUEMKQSH-UHFFFAOYSA-N 1,4-benzodiazepin-2-one Chemical compound O=C1C=NC=C2C=CC=CC2=N1 RGGLEJFUEMKQSH-UHFFFAOYSA-N 0.000 description 1
- HXBMIQJOSHZCFX-UHFFFAOYSA-N 1-(bromomethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CBr HXBMIQJOSHZCFX-UHFFFAOYSA-N 0.000 description 1
- BXCBUWKTXLWPSB-UHFFFAOYSA-N 1-(chloromethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CCl BXCBUWKTXLWPSB-UHFFFAOYSA-N 0.000 description 1
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- WODSGDBIRBLOSO-UHFFFAOYSA-N 1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-4-[4-(trifluoromethyl)benzoyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 WODSGDBIRBLOSO-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- FNMKURILMDWFEY-UHFFFAOYSA-N 1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-4-(1h-indole-6-carbonyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C=1C=C(CN2C(CN(CC3=CC=CC=C32)C(=O)C=2C=C3NC=CC3=CC=2)=O)C=CC=1C(=O)N1CC=CC1 FNMKURILMDWFEY-UHFFFAOYSA-N 0.000 description 1
- WMBRZVVKTZGKDZ-UHFFFAOYSA-N 1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-4-[4-(methylamino)benzoyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(NC)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CC=CC2)C2=CC=CC=C2C1 WMBRZVVKTZGKDZ-UHFFFAOYSA-N 0.000 description 1
- DREPONDJUKIQLX-UHFFFAOYSA-N 1-[ethenyl(ethoxy)phosphoryl]oxyethane Chemical compound CCOP(=O)(C=C)OCC DREPONDJUKIQLX-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- AMMBUJFMJOQABC-UHFFFAOYSA-N 1-carboxypropylazanium;chloride Chemical compound Cl.CCC(N)C(O)=O AMMBUJFMJOQABC-UHFFFAOYSA-N 0.000 description 1
- HQCZLEAGIOIIMC-UHFFFAOYSA-N 1-methoxy-2-methyl-3-nitrobenzene Chemical compound COC1=CC=CC([N+]([O-])=O)=C1C HQCZLEAGIOIIMC-UHFFFAOYSA-N 0.000 description 1
- MGBRGNWARSQECY-UHFFFAOYSA-N 1-methoxy-3-methyl-2-nitrobenzene Chemical compound COC1=CC=CC(C)=C1[N+]([O-])=O MGBRGNWARSQECY-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical group CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
- PLDLWHLVVCDBFP-UHFFFAOYSA-N 1h-1,4-diazepine-7-carboxylic acid Chemical compound OC(=O)C1=CC=NC=CN1 PLDLWHLVVCDBFP-UHFFFAOYSA-N 0.000 description 1
- GHTDODSYDCPOCW-UHFFFAOYSA-N 1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=C1 GHTDODSYDCPOCW-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- VBKYDEKRDVGCEW-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-8-carboxylic acid Chemical compound N1CCNCC2=C1C=C(C=C2)C(=O)O VBKYDEKRDVGCEW-UHFFFAOYSA-N 0.000 description 1
- GCTFDMFLLBCLPF-UHFFFAOYSA-N 2,5-dichloropyridine Chemical compound ClC1=CC=C(Cl)N=C1 GCTFDMFLLBCLPF-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- BWPZDLVOJNBEKI-UHFFFAOYSA-N 2-(chloromethyl)-4-methyl-1-nitrobenzene Chemical compound CC1=CC=C([N+]([O-])=O)C(CCl)=C1 BWPZDLVOJNBEKI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- XMMZVVPHSYJZKB-UHFFFAOYSA-N 2-[4-(4-chlorobenzoyl)-2-oxo-3,5-dihydro-1,4-benzodiazepin-1-yl]-n-pyridin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC(=O)NC=2C=CN=CC=2)C2=CC=CC=C2C1 XMMZVVPHSYJZKB-UHFFFAOYSA-N 0.000 description 1
- CGVNRGZQUIHLSR-UHFFFAOYSA-N 2-[4-(4-chlorobenzoyl)-2-oxo-3,5-dihydro-1,4-benzodiazepin-1-yl]acetic acid Chemical compound C1C(=O)N(CC(=O)O)C2=CC=CC=C2CN1C(=O)C1=CC=C(Cl)C=C1 CGVNRGZQUIHLSR-UHFFFAOYSA-N 0.000 description 1
- DTKBIPMCFUGAPA-UHFFFAOYSA-N 2-[6-chloro-4-(4-chlorobenzoyl)-2-oxo-3,5-dihydro-1,4-benzodiazepin-1-yl]-2-phenylacetonitrile Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(C(C#N)C=2C=CC=CC=2)C2=CC=CC(Cl)=C2C1 DTKBIPMCFUGAPA-UHFFFAOYSA-N 0.000 description 1
- XCSNRORTQRKCHB-UHFFFAOYSA-N 2-chloro-6-nitrotoluene Chemical compound CC1=C(Cl)C=CC=C1[N+]([O-])=O XCSNRORTQRKCHB-UHFFFAOYSA-N 0.000 description 1
- KQUQBPVYIURTNZ-UHFFFAOYSA-N 2-methyl-1-nitro-3-(trifluoromethyl)benzene Chemical compound CC1=C([N+]([O-])=O)C=CC=C1C(F)(F)F KQUQBPVYIURTNZ-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- MYSAXQPTXWKDPQ-UHFFFAOYSA-N 2-nitro-4-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O MYSAXQPTXWKDPQ-UHFFFAOYSA-N 0.000 description 1
- NAHHNSMHYCLMON-UHFFFAOYSA-N 2-pyridin-3-ylethanamine Chemical compound NCCC1=CC=CN=C1 NAHHNSMHYCLMON-UHFFFAOYSA-N 0.000 description 1
- IDLHTECVNDEOIY-UHFFFAOYSA-N 2-pyridin-4-ylethanamine Chemical compound NCCC1=CC=NC=C1 IDLHTECVNDEOIY-UHFFFAOYSA-N 0.000 description 1
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 1
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- DMGFVJVLVZOSOE-UHFFFAOYSA-N 3-amino-4-chlorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1Cl DMGFVJVLVZOSOE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- XDTTUTIFWDAMIX-UHFFFAOYSA-N 3-methyl-4-nitrobenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1[N+]([O-])=O XDTTUTIFWDAMIX-UHFFFAOYSA-N 0.000 description 1
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 1
- DINHSALAIUEYQD-UHFFFAOYSA-N 4-(3,4-dichlorobenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 DINHSALAIUEYQD-UHFFFAOYSA-N 0.000 description 1
- HMLCKYLAYOBKRZ-UHFFFAOYSA-N 4-(3-methoxybenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound COC1=CC=CC(C(=O)N2CC(=O)N(CC3CCN(CC3)C=3C=CN=CC=3)C3=CC=CC=C3C2)=C1 HMLCKYLAYOBKRZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GHJWZDQZLSXYTH-UHFFFAOYSA-N 4-(3h-benzimidazole-5-carbonyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C=1C=C(CN2C(CN(CC3=CC=CC=C32)C(=O)C=2C=C3NC=NC3=CC=2)=O)C=CC=1C(=O)N1CC=CC1 GHJWZDQZLSXYTH-UHFFFAOYSA-N 0.000 description 1
- LCIJBIZNNSYBDR-UHFFFAOYSA-N 4-(4-bromobenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Br)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 LCIJBIZNNSYBDR-UHFFFAOYSA-N 0.000 description 1
- PLXUEIIQRPALNN-UHFFFAOYSA-N 4-(4-chloro-2-fluorobenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound FC1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 PLXUEIIQRPALNN-UHFFFAOYSA-N 0.000 description 1
- XNEWBQUHQSYXJR-UHFFFAOYSA-N 4-(4-chloro-2-hydroxybenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound OC1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 XNEWBQUHQSYXJR-UHFFFAOYSA-N 0.000 description 1
- ZZQPYUAJYWERSW-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 ZZQPYUAJYWERSW-UHFFFAOYSA-N 0.000 description 1
- OWINTYREJUVHET-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[(3,4-dichlorophenyl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=C(Cl)C(Cl)=CC=2)C2=CC=CC=C2C1 OWINTYREJUVHET-UHFFFAOYSA-N 0.000 description 1
- VIZKJYHWRKIXLB-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[(4-fluorophenyl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(F)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 VIZKJYHWRKIXLB-UHFFFAOYSA-N 0.000 description 1
- ZIGYKKPREIDSTB-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[(4-nitrophenyl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 ZIGYKKPREIDSTB-UHFFFAOYSA-N 0.000 description 1
- BWLLSQLDJYTSDO-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[(4-phenylphenyl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C=2C=CC=CC=2)C2=CC=CC=C2C1 BWLLSQLDJYTSDO-UHFFFAOYSA-N 0.000 description 1
- LKQBQJJAYIGWIY-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(1-methyl-4,5-dihydroimidazol-2-yl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound CN1CCN=C1C(C=C1)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 LKQBQJJAYIGWIY-UHFFFAOYSA-N 0.000 description 1
- ZERVAPLXVPSIHF-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrol-1-ylmethyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(CN3CC=CC3)=CC=2)C2=CC=CC=C2C1 ZERVAPLXVPSIHF-UHFFFAOYSA-N 0.000 description 1
- GKYYZEKTYYZKMM-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CC=CC2)C2=CC=CC=C2C1 GKYYZEKTYYZKMM-UHFFFAOYSA-N 0.000 description 1
- IMFVDRFFFZKYOO-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-6-hydroxy-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound O=C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC=2C(O)=CC=CC=2N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 IMFVDRFFFZKYOO-UHFFFAOYSA-N 0.000 description 1
- GCMJLFRIRNZAAD-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-6-methoxy-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound O=C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC=2C(OC)=CC=CC=2N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 GCMJLFRIRNZAAD-UHFFFAOYSA-N 0.000 description 1
- ZOUGAIHBOQRGIG-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-7-methyl-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound O=C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC(C)=CC=C2N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 ZOUGAIHBOQRGIG-UHFFFAOYSA-N 0.000 description 1
- BFGMOJKRFSZHRT-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-(3-piperidin-1-ylpropyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CC=CC2)C2=CC(CCCN3CCCCC3)=CC=C2C1 BFGMOJKRFSZHRT-UHFFFAOYSA-N 0.000 description 1
- UXFXUDNLZGVUPA-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-(3-pyrrolidin-1-ylpropyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CC=CC2)C2=CC(CCCN3CCCC3)=CC=C2C1 UXFXUDNLZGVUPA-UHFFFAOYSA-N 0.000 description 1
- YNVQOXUDMYVFFU-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-(piperazin-1-ylmethyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CC=CC2)C2=CC(CN3CCNCC3)=CC=C2C1 YNVQOXUDMYVFFU-UHFFFAOYSA-N 0.000 description 1
- YOTUFMQPJNCONR-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-(piperidin-1-ylmethyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CC=CC2)C2=CC(CN3CCCCC3)=CC=C2C1 YOTUFMQPJNCONR-UHFFFAOYSA-N 0.000 description 1
- DIWZKZMMLZKPHJ-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-(pyrrolidin-1-ylmethyl)-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=O)N2CC=CC2)C2=CC(CN3CCCC3)=CC=C2C1 DIWZKZMMLZKPHJ-UHFFFAOYSA-N 0.000 description 1
- XPSCQYJNNKVKLJ-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-[(dimethylamino)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(CN(C)C)=CC=C2CN(C(=O)C=2C=CC(Cl)=CC=2)CC(=O)N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 XPSCQYJNNKVKLJ-UHFFFAOYSA-N 0.000 description 1
- JAPPVEKHGICHIS-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1CN(C)CCN1C(=O)CCC1=CC=C(CN(CC(=O)N2CC=3C=CC(=CC=3)C(=O)N3CC=CC3)C(=O)C=3C=CC(Cl)=CC=3)C2=C1 JAPPVEKHGICHIS-UHFFFAOYSA-N 0.000 description 1
- CXOSWDYMZSRRHH-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-[3-oxo-3-(4-propan-2-ylpiperazin-1-yl)propyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1CN(C(C)C)CCN1C(=O)CCC1=CC=C(CN(CC(=O)N2CC=3C=CC(=CC=3)C(=O)N3CC=CC3)C(=O)C=3C=CC(Cl)=CC=3)C2=C1 CXOSWDYMZSRRHH-UHFFFAOYSA-N 0.000 description 1
- DTQAIRDRYHOVPZ-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-8-methoxy-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(OC)=CC=C2CN(C(=O)C=2C=CC(Cl)=CC=2)CC(=O)N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 DTQAIRDRYHOVPZ-UHFFFAOYSA-N 0.000 description 1
- GHYUQDCFMKSNKZ-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carboximidoyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=N)N2CC=CC2)C2=CC=CC=C2C1 GHYUQDCFMKSNKZ-UHFFFAOYSA-N 0.000 description 1
- UVUNYWZZZZVZSG-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(2-methylsulfonylphenyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound CS(=O)(=O)C1=CC=CC=C1C(C=C1)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 UVUNYWZZZZVZSG-UHFFFAOYSA-N 0.000 description 1
- UJTLWAWTGFQFGL-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(dimethylamino)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(N(C)C)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 UJTLWAWTGFQFGL-UHFFFAOYSA-N 0.000 description 1
- IYHDVFUVQNEZQB-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(morpholine-4-carboximidoyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=N)N2CCOCC2)C2=CC=CC=C2C1 IYHDVFUVQNEZQB-UHFFFAOYSA-N 0.000 description 1
- BNUGNCKEPDBIEH-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(piperidine-1-carboximidoyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=N)N2CCCCC2)C2=CC=CC=C2C1 BNUGNCKEPDBIEH-UHFFFAOYSA-N 0.000 description 1
- XLSNPWCTWRVBRK-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-1-[[4-(pyrrolidine-1-carboximidoyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C(=N)N2CCCC2)C2=CC=CC=C2C1 XLSNPWCTWRVBRK-UHFFFAOYSA-N 0.000 description 1
- ULAKMKZHWCXOOD-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-2-oxo-1-[(4-piperidin-4-yloxyphenyl)methyl]-3,5-dihydro-1,4-benzodiazepine-7-carboxylic acid Chemical compound O=C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC(C(=O)O)=CC=C2N1CC(C=C1)=CC=C1OC1CCNCC1 ULAKMKZHWCXOOD-UHFFFAOYSA-N 0.000 description 1
- BFXGKFDGPANFHZ-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-2-oxo-1-[(4-piperidin-4-yloxyphenyl)methyl]-3,5-dihydro-1,4-benzodiazepine-8-carboxylic acid Chemical compound C12=CC(C(=O)O)=CC=C2CN(C(=O)C=2C=CC(Cl)=CC=2)CC(=O)N1CC(C=C1)=CC=C1OC1CCNCC1 BFXGKFDGPANFHZ-UHFFFAOYSA-N 0.000 description 1
- NLSMMJOFVKOQGJ-UHFFFAOYSA-N 4-(4-chlorobenzoyl)-2-oxo-1-[[4-(pyrrolidine-1-carbonyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepine-8-carboxylic acid Chemical compound C12=CC(C(=O)O)=CC=C2CN(C(=O)C=2C=CC(Cl)=CC=2)CC(=O)N1CC(C=C1)=CC=C1C(=O)N1CCCC1 NLSMMJOFVKOQGJ-UHFFFAOYSA-N 0.000 description 1
- NCQMUFPGUHHSOM-UHFFFAOYSA-N 4-(4-fluorobenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 NCQMUFPGUHHSOM-UHFFFAOYSA-N 0.000 description 1
- AJQHWQFEWDVCCS-UHFFFAOYSA-N 4-(4-methylbenzoyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(C)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 AJQHWQFEWDVCCS-UHFFFAOYSA-N 0.000 description 1
- FDUJVFIKQPFMCZ-UHFFFAOYSA-N 4-(6-chloropyridine-3-carbonyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=NC(Cl)=CC=C1C(=O)N1CC(=O)N(CC2CCN(CC2)C=2C=CN=CC=2)C2=CC=CC=C2C1 FDUJVFIKQPFMCZ-UHFFFAOYSA-N 0.000 description 1
- QMAHVAFURJBOFV-UHFFFAOYSA-N 4-(bromomethyl)-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(CBr)C([N+]([O-])=O)=C1 QMAHVAFURJBOFV-UHFFFAOYSA-N 0.000 description 1
- CQQSQBRPAJSTFB-UHFFFAOYSA-N 4-(bromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CBr)C=C1 CQQSQBRPAJSTFB-UHFFFAOYSA-N 0.000 description 1
- ZVCWJQIYDVQTSO-UHFFFAOYSA-N 4-(naphthalene-2-carbonyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)N(CC1=O)CC2=CC=CC=C2N1CC(CC1)CCN1C1=CC=NC=C1 ZVCWJQIYDVQTSO-UHFFFAOYSA-N 0.000 description 1
- XPHDRAQNXMWNTO-UHFFFAOYSA-N 4-(pyridine-3-carbonyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C=1C=CN=CC=1C(=O)N(CC1=O)CC2=CC=CC=C2N1CC(CC1)CCN1C1=CC=NC=C1 XPHDRAQNXMWNTO-UHFFFAOYSA-N 0.000 description 1
- PBQHINJTXVRCHL-UHFFFAOYSA-N 4-(pyridine-4-carbonyl)-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C=1C=NC=CC=1C(=O)N(CC1=O)CC2=CC=CC=C2N1CC(CC1)CCN1C1=CC=NC=C1 PBQHINJTXVRCHL-UHFFFAOYSA-N 0.000 description 1
- LUVXDMFUUZGFST-UHFFFAOYSA-N 4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxybenzoic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(C(O)=O)C=C1 LUVXDMFUUZGFST-UHFFFAOYSA-N 0.000 description 1
- OFIVYLHHTSGTMW-UHFFFAOYSA-N 4-[[4-(4-chlorobenzoyl)-2-oxo-3,5-dihydro-1,4-benzodiazepin-1-yl]methyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=CC=CC=C21 OFIVYLHHTSGTMW-UHFFFAOYSA-N 0.000 description 1
- BDXVUQIIIKBRBS-UHFFFAOYSA-N 4-[[4-(4-chlorobenzoyl)-2-oxo-3,5-dihydro-1,4-benzodiazepin-1-yl]methyl]benzonitrile Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C#N)C2=CC=CC=C2C1 BDXVUQIIIKBRBS-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- KLBMPWPNIRNDBU-UHFFFAOYSA-N 4-benzoyl-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C=1C=CC=CC=1C(=O)N(CC1=O)CC2=CC=CC=C2N1CC(CC1)CCN1C1=CC=NC=C1 KLBMPWPNIRNDBU-UHFFFAOYSA-N 0.000 description 1
- KZNXALJXBRSMFL-UHFFFAOYSA-N 4-bromo-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(Br)C=C1[N+]([O-])=O KZNXALJXBRSMFL-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- ZLPXBWMVZANJJQ-UHFFFAOYSA-N 4-chloro-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1F ZLPXBWMVZANJJQ-UHFFFAOYSA-N 0.000 description 1
- LWXFCZXRFBUOOR-UHFFFAOYSA-N 4-chloro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1O LWXFCZXRFBUOOR-UHFFFAOYSA-N 0.000 description 1
- UFEYMXHWIHFRBX-UHFFFAOYSA-N 4-chloro-2-methoxybenzoic acid Chemical compound COC1=CC(Cl)=CC=C1C(O)=O UFEYMXHWIHFRBX-UHFFFAOYSA-N 0.000 description 1
- JAHIPDTWWVYVRV-UHFFFAOYSA-N 4-chloro-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1[N+]([O-])=O JAHIPDTWWVYVRV-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- AVTLLLZVYYPGFX-UHFFFAOYSA-N 4-ethylbenzoyl chloride Chemical compound CCC1=CC=C(C(Cl)=O)C=C1 AVTLLLZVYYPGFX-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 1
- COWZPSUDTMGBAT-UHFFFAOYSA-N 5-bromothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)S1 COWZPSUDTMGBAT-UHFFFAOYSA-N 0.000 description 1
- QZLSBOVWPHXCLT-UHFFFAOYSA-N 5-chlorothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)S1 QZLSBOVWPHXCLT-UHFFFAOYSA-N 0.000 description 1
- VCNGNQLPFHVODE-UHFFFAOYSA-N 5-methylthiophene-2-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)S1 VCNGNQLPFHVODE-UHFFFAOYSA-N 0.000 description 1
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 1
- YQTVCYZYPSCIFJ-UHFFFAOYSA-N 6-chloro-4-(4-chlorobenzoyl)-1-[(1-piperidin-4-yloxycyclohexa-2,4-dien-1-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC2(C=CC=CC2)OC2CCNCC2)C2=CC=CC(Cl)=C2C1 YQTVCYZYPSCIFJ-UHFFFAOYSA-N 0.000 description 1
- FBGNNMNTNPNYIH-UHFFFAOYSA-N 6-chloro-4-(4-chlorobenzoyl)-1-[[4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC=2C=CC(=CC=2)C=2NCCCN=2)C2=CC=CC(Cl)=C2C1 FBGNNMNTNPNYIH-UHFFFAOYSA-N 0.000 description 1
- DZRRYVULGMBYKS-UHFFFAOYSA-N 6-chloro-4-(4-chlorobenzoyl)-1-[[4-(1-methyl-4,5-dihydroimidazol-2-yl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound CN1CCN=C1C(C=C1)=CC=C1CN1C(=O)CN(C(=O)C=2C=CC(Cl)=CC=2)CC2=C(Cl)C=CC=C21 DZRRYVULGMBYKS-UHFFFAOYSA-N 0.000 description 1
- GNRAJGHLALFVKF-UHFFFAOYSA-N 7-chloro-4-(4-chlorobenzoyl)-1-[(1-piperidin-4-yloxycyclohexa-2,4-dien-1-yl)methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CC(=O)N(CC2(C=CC=CC2)OC2CCNCC2)C2=CC=C(Cl)C=C2C1 GNRAJGHLALFVKF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZHKCVLSAWVBQHB-UHFFFAOYSA-N 8-amino-4-(4-chlorobenzoyl)-1-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methyl]-3,5-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(N)=CC=C2CN(C(=O)C=2C=CC(Cl)=CC=2)CC(=O)N1CC(C=C1)=CC=C1C(=O)N1CC=CC1 ZHKCVLSAWVBQHB-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- IJDQFBLVDCRTLR-UHFFFAOYSA-N CCOC(=O)C(CC1=C(C=C(C=C1)OC)[N+](=O)[O-])N Chemical compound CCOC(=O)C(CC1=C(C=C(C=C1)OC)[N+](=O)[O-])N IJDQFBLVDCRTLR-UHFFFAOYSA-N 0.000 description 1
- KDKCOOACAYUDII-UHFFFAOYSA-N CCOC(=O)C(CC1=C(C=CC=C1OC)[N+](=O)[O-])N Chemical compound CCOC(=O)C(CC1=C(C=CC=C1OC)[N+](=O)[O-])N KDKCOOACAYUDII-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ZVIDMSBTYRSMAR-UHFFFAOYSA-N N-Methyl-4-aminobenzoate Chemical compound CNC1=CC=C(C(O)=O)C=C1 ZVIDMSBTYRSMAR-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- OHDBYQSGLSTIHF-UHFFFAOYSA-N benzenesulfonic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.OS(=O)(=O)C1=CC=CC=C1 OHDBYQSGLSTIHF-UHFFFAOYSA-N 0.000 description 1
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002946 cyanobenzyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HRCNNCXARRRSFB-UHFFFAOYSA-N ethyl 2-[(2-amino-5-chlorophenyl)methyl-(4-chlorobenzoyl)amino]acetate Chemical compound C=1C=C(Cl)C=CC=1C(=O)N(CC(=O)OCC)CC1=CC(Cl)=CC=C1N HRCNNCXARRRSFB-UHFFFAOYSA-N 0.000 description 1
- ZFDGTZREUMGQME-UHFFFAOYSA-N ethyl 2-[(2-nitrophenyl)methylamino]acetate Chemical compound CCOC(=O)CNCC1=CC=CC=C1[N+]([O-])=O ZFDGTZREUMGQME-UHFFFAOYSA-N 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- IENZCGNHSIMFJE-UHFFFAOYSA-N indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=CC2=C1 IENZCGNHSIMFJE-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006262 isopropyl amino sulfonyl group Chemical group 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JHBRRIPELWGPIS-UHFFFAOYSA-N methyl 3-[2-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]-3-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methylamino]phenyl]propanoate Chemical compound C=1C=C(Cl)C=CC=1C(=O)CCOC(=O)CNCC=1C(CCC(=O)OC)=CC=CC=1NCC(C=C1)=CC=C1C(=O)N1CC=CC1 JHBRRIPELWGPIS-UHFFFAOYSA-N 0.000 description 1
- MQIXWOCGFABVPH-UHFFFAOYSA-N methyl 3-[2-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]-3-[[4-(pyrrolidine-1-carbonyl)phenyl]methylamino]phenyl]propanoate Chemical compound C=1C=C(Cl)C=CC=1C(=O)CCOC(=O)CNCC=1C(CCC(=O)OC)=CC=CC=1NCC(C=C1)=CC=C1C(=O)N1CCCC1 MQIXWOCGFABVPH-UHFFFAOYSA-N 0.000 description 1
- FHSHFZVPQHWRFA-UHFFFAOYSA-N methyl 3-[3-amino-4-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]phenyl]propanoate Chemical compound NC1=CC(CCC(=O)OC)=CC=C1CNCC(=O)OCCC(=O)C1=CC=C(Cl)C=C1 FHSHFZVPQHWRFA-UHFFFAOYSA-N 0.000 description 1
- ILZBHCVSOIISOT-UHFFFAOYSA-N methyl 3-[4-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]-3-nitrophenyl]prop-2-enoate Chemical compound [O-][N+](=O)C1=CC(C=CC(=O)OC)=CC=C1CNCC(=O)OCCC(=O)C1=CC=C(Cl)C=C1 ILZBHCVSOIISOT-UHFFFAOYSA-N 0.000 description 1
- DCJNIKKRJGQKGN-UHFFFAOYSA-N methyl 3-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]-4-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methylamino]benzoate Chemical compound C=1C=C(Cl)C=CC=1C(=O)CCOC(=O)CNCC1=CC(C(=O)OC)=CC=C1NCC(C=C1)=CC=C1C(=O)N1CC=CC1 DCJNIKKRJGQKGN-UHFFFAOYSA-N 0.000 description 1
- UJRUTLNKILHFTE-UHFFFAOYSA-N methyl 3-amino-4-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]benzoate Chemical compound NC1=CC(C(=O)OC)=CC=C1CNCC(=O)OCCC(=O)C1=CC=C(Cl)C=C1 UJRUTLNKILHFTE-UHFFFAOYSA-N 0.000 description 1
- RJMDNTZFBDBJBL-UHFFFAOYSA-N methyl 4-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]-3-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]methylamino]benzoate Chemical compound C=1C=C(C(=O)N2CC=CC2)C=CC=1CNC1=CC(C(=O)OC)=CC=C1CNCC(=O)OCCC(=O)C1=CC=C(Cl)C=C1 RJMDNTZFBDBJBL-UHFFFAOYSA-N 0.000 description 1
- KAOXEITUOPEBQP-UHFFFAOYSA-N methyl 4-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]-3-[[4-(pyrrolidine-1-carbonyl)phenyl]methylamino]benzoate Chemical compound C=1C=C(C(=O)N2CCCC2)C=CC=1CNC1=CC(C(=O)OC)=CC=C1CNCC(=O)OCCC(=O)C1=CC=C(Cl)C=C1 KAOXEITUOPEBQP-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- XNLBCXGRQWUJLU-UHFFFAOYSA-N naphthalene-2-carbonyl chloride Chemical compound C1=CC=CC2=CC(C(=O)Cl)=CC=C21 XNLBCXGRQWUJLU-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- LRYMQBSZNWIAKP-UHFFFAOYSA-N tert-butyl 4-(2-formylphenoxy)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=CC=C1C=O LRYMQBSZNWIAKP-UHFFFAOYSA-N 0.000 description 1
- JVRJJDPEIIEIIA-UHFFFAOYSA-N tert-butyl 4-[4-(hydroxymethyl)phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(CO)C=C1 JVRJJDPEIIEIIA-UHFFFAOYSA-N 0.000 description 1
- CUHOALHLJQGTNQ-UHFFFAOYSA-N tert-butyl 4-[4-[[2-[[[2-[3-(4-chlorophenyl)-3-oxopropoxy]-2-oxoethyl]amino]methyl]-4-methoxycarbonylanilino]methyl]phenoxy]piperidine-1-carboxylate Chemical compound C=1C=C(Cl)C=CC=1C(=O)CCOC(=O)CNCC1=CC(C(=O)OC)=CC=C1NCC(C=C1)=CC=C1OC1CCN(C(=O)OC(C)(C)C)CC1 CUHOALHLJQGTNQ-UHFFFAOYSA-N 0.000 description 1
- BJEMKTCQUQQBOW-UHFFFAOYSA-N tert-butyl 4-[4-[[4-chloro-2-[[(4-chlorobenzoyl)-(2-ethoxy-2-oxoethyl)amino]methyl]anilino]methyl]phenoxy]piperidine-1-carboxylate Chemical compound C=1C=C(Cl)C=CC=1C(=O)N(CC(=O)OCC)CC1=CC(Cl)=CC=C1NCC(C=C1)=CC=C1OC1CCN(C(=O)OC(C)(C)C)CC1 BJEMKTCQUQQBOW-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000294240 | 2000-09-27 | ||
PCT/JP2001/008352 WO2002026732A1 (fr) | 2000-09-27 | 2001-09-26 | Derive de benzodiazepine |
Publications (1)
Publication Number | Publication Date |
---|---|
SK3632003A3 true SK3632003A3 (en) | 2003-09-11 |
Family
ID=18776884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK363-2003A SK3632003A3 (en) | 2000-09-27 | 2001-09-26 | Benzodiazepine derivatives, pharmaceutical composition comprising same and their use |
Country Status (18)
Country | Link |
---|---|
US (1) | US6825191B2 (ja) |
EP (1) | EP1329450A4 (ja) |
JP (1) | JPWO2002026732A1 (ja) |
KR (1) | KR20030031196A (ja) |
CN (1) | CN1476446A (ja) |
AU (2) | AU9224101A (ja) |
BR (1) | BR0114276A (ja) |
CA (1) | CA2423902A1 (ja) |
CZ (1) | CZ2003893A3 (ja) |
HU (1) | HUP0303074A3 (ja) |
IL (1) | IL155035A0 (ja) |
MX (1) | MXPA03002649A (ja) |
NO (1) | NO20031354L (ja) |
PL (1) | PL362048A1 (ja) |
RU (1) | RU2003112257A (ja) |
SK (1) | SK3632003A3 (ja) |
WO (1) | WO2002026732A1 (ja) |
ZA (1) | ZA200302245B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005298343A (ja) * | 2002-03-27 | 2005-10-27 | Ajinomoto Co Inc | ベンゾジアゼピン誘導体 |
JP2006151807A (ja) * | 2002-12-19 | 2006-06-15 | Ajinomoto Co Inc | ベンゾジアゼピン誘導体 |
CA2560111A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
EP1847527A4 (en) | 2005-02-02 | 2009-04-08 | Ajinomoto Kk | NEW BENZAMIDINE DERIVATIVE |
JP2009501721A (ja) * | 2005-07-12 | 2009-01-22 | アカディア ファーマシューティカルズ インコーポレイテッド | レチノイン酸受容体における活性を伴う化合物 |
EA017249B8 (ru) * | 2007-05-10 | 2013-01-30 | Олбани Молекьюлар Рисерч, Инк. | Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
AU2012312654B2 (en) | 2011-09-19 | 2017-04-13 | Gencia Corporation | Modified creatine compounds |
ES2912276T3 (es) | 2015-04-07 | 2022-05-25 | Ela Pharma Ltd | Composiciones para tratar y/o prevenir necrosis celular o tisular que seleccionan como diana específicamente catepsina C y/o CELA1 y/o CELA3A y/o enzimas estructuralmente relacionadas con las mismas |
TWI736619B (zh) * | 2016-05-06 | 2021-08-21 | 西班牙商艾斯提夫製藥公司 | 用於治療疼痛及相關狀況的新四氫嘧啶並二吖呯及二氫吡啶並二吖呯化合物 |
EP3624797A4 (en) * | 2017-05-17 | 2021-07-21 | Denali Therapeutics Inc. | CINEMA JAM AND USES THEREOF |
CN116348109A (zh) * | 2020-09-17 | 2023-06-27 | 浙江海正药业股份有限公司 | 哌嗪类衍生物及其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5493020A (en) * | 1993-07-29 | 1996-02-20 | Genentech, Inc. | Tricyclic inhibitors of the GPIIb IIIa receptor |
WO1999040075A1 (fr) * | 1998-02-05 | 1999-08-12 | Takeda Chemical Industries, Ltd. | Derives de sulfamide, leur procede de production et leur utilisation |
-
2001
- 2001-09-26 KR KR10-2003-7004458A patent/KR20030031196A/ko not_active Application Discontinuation
- 2001-09-26 AU AU9224101A patent/AU9224101A/xx active Pending
- 2001-09-26 HU HU0303074A patent/HUP0303074A3/hu unknown
- 2001-09-26 CA CA002423902A patent/CA2423902A1/en not_active Abandoned
- 2001-09-26 WO PCT/JP2001/008352 patent/WO2002026732A1/ja not_active Application Discontinuation
- 2001-09-26 EP EP01972490A patent/EP1329450A4/en not_active Withdrawn
- 2001-09-26 MX MXPA03002649A patent/MXPA03002649A/es unknown
- 2001-09-26 BR BR0114276-3A patent/BR0114276A/pt not_active IP Right Cessation
- 2001-09-26 IL IL15503501A patent/IL155035A0/xx unknown
- 2001-09-26 RU RU2003112257/04A patent/RU2003112257A/ru not_active Application Discontinuation
- 2001-09-26 SK SK363-2003A patent/SK3632003A3/sk unknown
- 2001-09-26 JP JP2002531116A patent/JPWO2002026732A1/ja active Pending
- 2001-09-26 AU AU2001292241A patent/AU2001292241B2/en not_active Ceased
- 2001-09-26 CN CNA018195466A patent/CN1476446A/zh active Pending
- 2001-09-26 PL PL01362048A patent/PL362048A1/xx not_active Application Discontinuation
- 2001-09-26 CZ CZ2003893A patent/CZ2003893A3/cs unknown
-
2003
- 2003-03-20 ZA ZA200302245A patent/ZA200302245B/en unknown
- 2003-03-25 NO NO20031354A patent/NO20031354L/no unknown
- 2003-03-27 US US10/397,219 patent/US6825191B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU9224101A (en) | 2002-04-08 |
KR20030031196A (ko) | 2003-04-18 |
JPWO2002026732A1 (ja) | 2004-07-08 |
US20030186969A1 (en) | 2003-10-02 |
ZA200302245B (en) | 2004-03-23 |
AU2001292241B2 (en) | 2005-12-22 |
HUP0303074A2 (hu) | 2003-12-29 |
CN1476446A (zh) | 2004-02-18 |
EP1329450A1 (en) | 2003-07-23 |
CZ2003893A3 (cs) | 2003-08-13 |
EP1329450A4 (en) | 2005-08-31 |
PL362048A1 (en) | 2004-10-18 |
CA2423902A1 (en) | 2003-03-26 |
BR0114276A (pt) | 2003-06-24 |
WO2002026732A1 (fr) | 2002-04-04 |
IL155035A0 (en) | 2003-10-31 |
NO20031354D0 (no) | 2003-03-25 |
NO20031354L (no) | 2003-05-02 |
MXPA03002649A (es) | 2003-09-25 |
RU2003112257A (ru) | 2004-10-27 |
HUP0303074A3 (en) | 2007-08-28 |
US6825191B2 (en) | 2004-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4939401B2 (ja) | TAFIa阻害剤として用いるイミダゾール誘導体 | |
AU2009311756B2 (en) | Modulators of amyloid beta. | |
EP0691960B1 (en) | Antipsychotic benzimidazole derivatives | |
SK8394A3 (en) | Fivemembers heterocyclecs method of their production and medicine containing these matters | |
KR101171433B1 (ko) | 이미다졸리딘온 유도체 | |
HU223754B1 (hu) | Diszubsztituált biciklusos, heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
WO1999040075A1 (fr) | Derives de sulfamide, leur procede de production et leur utilisation | |
JP3159711B2 (ja) | 新規2,3−ジオキソ−1,2,3,4−テトラヒドロ−キノキサリニル誘導体 | |
JP2000516913A (ja) | 細胞増殖抑制剤および免疫抑制剤としてのピリジルアルケン―およびピリジルアルキン―酸アミド類 | |
WO2007088041A1 (en) | Compounds for the inhibition of integrins and use thereof | |
CZ2002323A3 (cs) | Substituované oxoazaheterocyklylové sloučeniny a farmaceutické prostředky, které je obsahují | |
JP2000512652A (ja) | 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび/またはピリジルアルキン酸アミド類の用途 | |
HUT61984A (en) | Process for producing condensed imidazole derivatives and pharmaceutical compositions comprising same | |
AU709070B2 (en) | Novel compounds with platelet aggregation inhibitor activity | |
JP2000512651A (ja) | 細胞増殖抑制剤および免疫抑制剤としての新規なピリジルアルカン酸アミド類 | |
CA2853833A1 (en) | Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto | |
WO2005111037A1 (en) | Beta-carbolines useful for treating inflammatory disease | |
MXPA02006509A (es) | Nuevas piperidinas sustituidas, medicamentos que contienes estos compuestos y procedimientos para su preparacion. | |
CA2863132A1 (en) | Isoquinoline and naphthyridine derivatives | |
SK3632003A3 (en) | Benzodiazepine derivatives, pharmaceutical composition comprising same and their use | |
EA009121B1 (ru) | Бета-карболины, применяемые для лечения воспалительных заболеваний | |
HU211202A9 (en) | Imidazopyridine paf/h 1 antagonists | |
CN101248076A (zh) | 作为促代谢型谷氨酸盐受体拮抗剂的炔哌嗪类 | |
CA2383492A1 (en) | Acylhydrazine derivatives, their production and use | |
CA3210102A1 (en) | Diazepine derivatives useful in the treatment of clostridium difficile |